Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirogacestat in Chemoresistant TNBC
NCT02338531Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2015
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of nirogacestat in triple-negative breast cancer (TNBC), sponsored by Institut Jules Bordet. Planned start Jun 2015; status: withdrawn.
02
Drugs
nirogacestat
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02338531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338531.